DP-VPA D-Pharm.

Area of Science:

• Pharmacology and Drug Development
• Neurology
• Biotechnology

Background:

• Shire is developing DP-VPA, a prodrug of valproic acid (VPA), for severe epilepsy, status epilepticus, acute repetitive seizures, bipolar disorder, and migraine.
• DP-VPA is based on D-Pharm's Regulation Activation of Prodrugs (RAP) technology, designed for intracellular activation in diseased tissues.

Purpose of the Study:

• To evaluate the potential of DP-VPA as a novel therapeutic agent for severe epilepsy and related neurological and psychiatric conditions.
• To assess the efficacy and safety of DP-VPA through various clinical trial phases.

Main Methods:

• Phase I trials completed by March 2000.
• Phase II trials initiated in October 2000 for epilepsy, bipolar disorder, and migraine, ongoing as of November 2001.
• Multicenter, multinational Phase II trials of SPD-421 (DP-VPA) initiated in October 2001 for complex partial seizures.

Main Results:

• DP-VPA utilizes RAP technology, where disease pathology activates the prodrug upon cellular internalization.
• A patent (US-06077837) was granted for novel prodrugs with enhanced cellular penetration.
• Analyst predictions for market launch varied, with estimates for 2003-2004 and projected peak sales ranging from $200 million to significant annual revenues.

Conclusions:

• DP-VPA represents a novel approach to drug delivery, leveraging targeted activation for potential therapeutic benefits in epilepsy and other conditions.
• Clinical development is progressing through Phase II trials, with decisions on the compound's future anticipated in late 2002.
• Market analysts project significant commercial potential for DP-VPA, contingent on regulatory approval.